Latest Clinical Trials News

Pathkey.AI has teamed up with Armstrong Clinical to blend AI-driven trial predictions with expert clinical strategy, aiming to boost early-phase trial success and accelerate drug development in Australia and beyond.

NeuroScientific Biopharmaceuticals has initiated treatment of its fourth patient under the Special Access Scheme for StemSmart™, progressing towards a Phase 2 trial targeting severe Crohn’s disease.

Invex Therapeutics Ltd has had its trading suspension lifted following an announcement of new board and officer appointments, signaling a fresh chapter for the biotech company.

Chimeric Therapeutics has responded to ASX inquiries regarding the disclosure timing and materiality of new clinical data from its ADVENT-AML trial, emphasizing compliance with continuous disclosure rules and the careful verification of promising patient responses.

Immuron Limited has secured FDA approval for its IMM-529 Investigational New Drug application, clearing the way for a Phase 2 clinical trial targeting Clostridioides difficile infection. This milestone marks a significant step forward for a novel oral antibody therapy addressing a critical infectious disease with high recurrence rates.

ReNerve Limited is scaling up its clinical trial for the NervAlign® Nerve Cuff following promising interim results that show significant pain reduction in nerve repair patients. The expanded study aims to solidify evidence for broader regulatory approval and market adoption.

Artrya secures participation from Mass General Brigham, a leading U.S. cardiovascular research center, in its pivotal SAPPHIRE Study launching in early 2026. This collaboration aims to validate Artrya’s AI-powered Salix platform for earlier and more effective coronary artery disease detection.

Tryptamine Therapeutics has raised $6.1 million to fast-track clinical development of its IV-infused psilocin drug TRP-8803, targeting binge eating disorder and other neuropsychiatric conditions.

Imagion Biosystems reports encouraging findings from its Wayne State University collaboration, supporting a lower dose for its MagSense® HER2 imaging agent ahead of a planned FDA IND submission in Q4 2025.

TrivarX Limited has exercised its option to acquire the innovative Stabl-Im brain imaging technology, aiming to revolutionize early detection of brain tumours pending shareholder approval.

Imricor Medical Systems and Amsterdam UMC have completed the first-ever ischemic ventricular tachycardia ablation fully guided by real-time MRI, marking a major advance in cardiac electrophysiology.

Immutep Limited has received a significant A$4.6 million cash payment from the French government’s R&D tax incentive scheme, supporting its ongoing immunotherapy clinical programs.